CTSD and breast cancer: Cathepsin D expression significantly predicts poor prognosis in breast cancer and is associated with aggressive clinicopathological features and worse outcomes, including shorter breast cancer-specific survival (BCSS), higher risk of recurrence and distant metastasis, suggesting its potential as a prognostic biomarker and therapeutic target.